Double blind trial involving: Teorema, a new antirheumatic, vs. indometacin in rheumatoid diseases.
Teorema and indometacin were administered to patients with degenerative and inflammatory joint diseases and degenerative vertebral column diseases for a period of 21 days. 24 patients were included in the 3 groups distinguished by diagnostic criteria. The daily Teorema dose was 420 mg in 21 cases and 210 mg in 3 cases; that of indometacin was 150 mg in 22 cases and 75 mg in 2 cases. Both drugs were given orally as capsules (25 mg indometacin/capsule and 70 mg Teorema/capsule). Both compounds produced a highly significant improvement of symptoms. Laboratory tests at regular intervals failed to reveal any substantial deviations from normal in both treatment groups. In conclusion, the results of the double blind trial suggest that Teorema, a new anti-inflammatory substance, when administered at a dose of approximately 420 mg/day, produces a beneficial effect in many rheumatoid conditions, while causing remarkably few side effects.